Home  /  Medications for Opioid Use Disorder

TREATMENT OPTIONS

Medications for Opioid Use Disorder: Buprenorphine, Methadone & Naltrexone

A neutral, evidence-based guide to the three FDA-approved medications for opioid use disorder: what they are, how they work, and what questions to ask a clinician.

EVIDENCE LEVEL: ESTABLISHED / CLINICAL GUIDANCE

· 8 min read

Opioid use disorder (OUD) is a treatable medical condition. Three medications are FDA-approved specifically for its treatment: buprenorphine, methadone, and naltrexone. Collectively they are referred to as Medications for Opioid Use Disorder (MOUD), sometimes also called medication-assisted treatment (MAT).

SAMHSA identifies these three as the evidence-based cornerstone of OUD treatment. Used in combination with counseling and support services, they significantly reduce cravings, prevent relapse, lower overdose mortality, and improve long-term outcomes. [1]

This page provides a clear overview of each medication, a neutral comparison, and answers to common questions, including the one asked most often: "Is this just replacing one addiction with another?"

QUICK ANSWER

Buprenorphine, methadone, and naltrexone are the three FDA-approved medications for OUD. All three reduce the risk of relapse and overdose death. They work through different mechanisms and suit different clinical situations. None is universally "best": the right choice depends on individual circumstances and should be made with a clinician.

What Is MOUD?

MOUD refers to the use of FDA-approved medications, in combination with counseling and psychosocial support, to treat opioid use disorder. The goal is not simply to manage withdrawal symptoms, but to address the longer-term neurobiological and behavioral dimensions of OUD.

MOUD is grounded in decades of research. It is the standard of care recommended by SAMHSA, the American Society of Addiction Medicine (ASAM), and major international health bodies. [1, 2]

Why Medication May Be Recommended

After acute withdrawal, many people return to opioid use, not because of weak willpower, but because:

• Cravings driven by changes in brain reward circuits persist long after physical withdrawal resolves

• Stress, environmental cues, and emotional triggers can produce powerful urges to use

• Tolerance drops during abstinence, meaning a return to use at a previous dose can be fatal

• The underlying neurobiological adaptations of OUD do not fully reverse in a short timeframe

MOUD medications work with the brain's opioid receptor system, rather than demanding that the system immediately normalize, to reduce cravings and block the reinforcing effects of illicit opioids. Evidence consistently shows that MOUD reduces overdose deaths, reduces illicit opioid use, and improves quality of life. [1]

The Three Medications

Buprenorphine

Partial opioid agonist

Buprenorphine is a partial opioid agonist: it activates mu-opioid receptors, but less strongly than full agonists like heroin or oxycodone. This partial activation is enough to reduce cravings and withdrawal symptoms without producing significant euphoria at therapeutic doses. It also has a "ceiling effect" on respiratory depression, making it much safer in overdose than full agonists.

Common formulations

Sublingual film (Suboxone, buprenorphine/naloxone), sublingual tablets (Subutex), monthly injectable (Sublocade), six-month implant (Probuphine).

Naloxone combination

Most formulations combine buprenorphine with naloxone (an opioid antagonist) to deter injection misuse. When taken as directed sublingually, the naloxone is minimally absorbed and has no meaningful effect.

Access

Can be prescribed by certified physicians, nurse practitioners, and physician assistants, including in office-based and telehealth settings. Since 2023, the X-waiver requirement has been eliminated in the U.S., broadening prescriber access significantly.

Induction

Buprenorphine must be initiated when the person is in mild-to-moderate withdrawal (not in a fully saturated state) to avoid precipitated withdrawal.

Duration

Can be used short-term for withdrawal management or long-term for OUD treatment. Evidence generally supports longer duration of treatment for better outcomes.

SAMHSA describes buprenorphine as reducing illicit opioid use and increasing treatment retention. [1]

See: Buprenorphine Explained →

Methadone

Full opioid agonist

Methadone is a full opioid agonist with a long half-life (24–36+ hours). At stable therapeutic doses, it eliminates withdrawal symptoms and reduces cravings throughout the day without producing euphoria, because blood levels remain stable rather than spiking.

Treatment setting

For OUD treatment, methadone must be dispensed through federally licensed Opioid Treatment Programs (OTPs), typically as a daily oral dose administered at a clinic.

Stability

Stable patients may earn take-home doses over time, reducing the burden of daily clinic visits.

Safety considerations

Methadone has a narrow therapeutic window and can affect heart rhythm (QT prolongation) at higher doses. Dose adjustments require clinical monitoring.

Long-term use

Research supports long-term methadone maintenance. Stopping methadone requires a supervised, gradual taper: abrupt discontinuation is not recommended.

Who it may suit

People who have not responded to buprenorphine, those requiring a more structured treatment setting, or those with more severe OUD.

See: Methadone Explained →

Naltrexone

Opioid antagonist

Naltrexone is an opioid antagonist: it blocks opioid receptors entirely, preventing any opioid from producing its effects. Unlike buprenorphine and methadone, it has no opioid agonist activity and cannot be misused to get high.

Formulations

Oral tablet (ReVia, daily) or extended-release injectable (Vivitrol, monthly).

Opioid-free requirement

Because naltrexone is an antagonist, it will precipitate severe, immediate withdrawal if taken while opioids are still in the system. A person must be fully opioid-free for 7–10 days (longer for methadone) before initiation.

No physical dependence

Naltrexone does not produce physical dependence. Stopping it does not cause withdrawal.

Mechanism

By blocking opioid receptors, naltrexone removes the reinforcing effect of opioids: if a person uses while on naltrexone, they will feel little or no effect.

Adherence

Adherence with oral naltrexone can be a challenge. The monthly injectable formulation (Vivitrol) addresses this by removing the need for daily dosing.

Who it may suit

People who are highly motivated, have completed opioid detox, prefer a non-opioid treatment, or have professional/legal reasons to avoid agonist medications.

See: Naltrexone Explained →

Comparing the Three Medications

Feature

Buprenorphine

Methadone

Naltrexone

Medication type

Partial opioid agonist

Full opioid agonist

Opioid antagonist

Helps with withdrawal

Yes

Yes

No (requires prior detox)

Reduces cravings

Yes

Yes

Yes (by blocking reward)

Physical dependence produced

Yes

Yes

No

Long-term use supported by evidence

Yes

Yes

Yes (adherence varies)

Access / setting

Office-based, telehealth, ED

Licensed OTP clinic (daily)

Office-based, monthly injectable

Opioid-free period required

Must be in mild withdrawal

No

7–10+ days fully opioid-free

Overdose safety

Higher (ceiling effect)

Lower (requires monitoring)

Highest (no agonist activity)

"Is MOUD Just Replacing One Addiction With Another?"

This is the most common question, and the most important one to address honestly.

The short answer: No. SAMHSA explicitly describes MOUD medications as evidence-based treatments, not as substituting one drug for another. [1]

Here is why the comparison does not hold up:

• OUD involves compulsive, harmful use despite negative consequences. A person on a stable therapeutic dose of buprenorphine or methadone is not experiencing compulsive, harmful use: they are taking a medication as prescribed that allows them to function normally.

• The neurobiological goals are different. MOUD medications stabilize the opioid receptor system at a consistent level, rather than producing the spikes and crashes of active opioid use that drive the cycle of compulsive behavior.

• Functional outcomes improve. Research shows people on MOUD have better employment, family, and health outcomes compared to those who attempt abstinence-only approaches.

• Mortality decreases significantly. MOUD reduces overdose deaths. The "replacement addiction" framing, when used to justify withholding effective treatment, contributes to preventable deaths.

The more accurate analogy is insulin for diabetes or blood pressure medication for hypertension: a chronic condition managed with medication that allows the person to live a healthy, functional life.

What Happens If Someone Wants to Stop MOUD?

This is a decision that should be made with careful clinical planning, not abruptly.

• Stopping buprenorphine or methadone abruptly will produce withdrawal and significantly increase relapse risk.

• A supervised taper is the standard approach, individualized to the person's situation.

• There is no standard "right" duration of MOUD. Some people choose to continue long-term; others eventually taper successfully. Both are valid outcomes.

• The decision to discontinue MOUD should never be driven by external pressure: stigma, cost, or a provider's preference: but by the person's own goals, medical situation, and readiness, assessed collaboratively with a clinician.

Do not stop MOUD abruptly without clinical guidance. Abrupt discontinuation significantly increases the risk of relapse and, because tolerance drops rapidly, the risk of a fatal overdose on return to use.

MOUD vs. Detox

Detox (withdrawal management) and MOUD are not equivalent. Detox manages the physical symptoms of withdrawal: it does not treat opioid use disorder. Evidence consistently shows that detox alone, without ongoing MOUD or other treatment, is associated with high rates of return to use. [2]

Detox can be an important first step, but for most people with OUD, it should be followed by ongoing treatment, of which MOUD is the most evidence-supported form. See: MOUD vs. Detox: What's the Difference?

Questions to Ask a Clinician

If you are considering MOUD, these questions can help you make an informed decision:

1. Which medication would you recommend for my situation, and why?

2. What does the induction process look like: what do I need to do first?

3. How will we monitor my progress and adjust the dose?

4. What are the most common side effects I should expect?

5. How long do most of your patients stay on this medication?

6. What happens if I miss a dose or want to stop?

7. What counseling or support services do you recommend alongside medication?

8. What does discontinuation look like when/if I choose to stop?

For a comprehensive preparation guide: How to Prepare for a Conversation With a Treatment Provider

Finding Treatment

SAMHSA Helpline

1-800-662-4357 (free, confidential, 24/7)

FindTreatment.gov

findtreatment.gov: treatment program locator

Prescriber Locator

samhsa.gov: SAMHSA buprenorphine practitioner locator

Key Takeaways

• Buprenorphine, methadone, and naltrexone are FDA-approved, evidence-based treatments for OUD.

• MOUD reduces overdose deaths, illicit opioid use, and relapse, with strong evidence across decades of research.

• Each medication works differently and suits different clinical situations. No single option is universally "best."

• MOUD is not "replacing one addiction with another." It is treating a medical condition with proven medicine.

• Stopping MOUD should be planned with a clinician: abrupt discontinuation significantly increases risk.

• Detox alone is not equivalent to OUD treatment.

Sources

1. SAMHSA. Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP) 63. 2021. SAMHSA.gov

2. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies, tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063-2066. PubMed

3. Mattick RP, et al. Methadone maintenance versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009. PubMed

4. CDC. Evidence-Based Overdose Prevention Strategies. CDC.gov

This page provides general educational information. MOUD decisions should be made in collaboration with a licensed healthcare provider. Last reviewed: August 2026. For educational purposes only.

Opiate Freedom Foundation is affiliated with PowerMade.com, which sells supplements.